Top

Published in:

Open Access 01-12-2023 | COVID-19 | Research

Epidemiological, clinical, therapeutic features and predictors of death among COVID-19 patients hospitalized in Parakou: a cross-sectional study in Northern Benin

Authors: Attinsounon Cossi Angelo, Yamongbè Clodel, Codjo Léopold, Adé Serge, Mama Cissé Ibrahim, Attinon Julien, Klikpezo Roger, Savi de Tovè Kofi-Mensa

Published in: BMC Infectious Diseases | Issue 1/2023

Abstract

Background

COVID-19 is an emerging contagious infection with polymorphic clinical manifestations. The purpose of this study was to describe the epidemiological, clinical, therapeutic features and identify the predictors of mortality among COVID-19 hospitalized cases in Parakou.

Methods

This was a cross-sectional, descriptive and analytic study. Systematic recruitment was used to include all patients hospitalized with COVID-19 from May 8, 2020, to December 31, 2021, whose medical records were available and usable. The variables studied were clinical and paraclinical signs, diagnostic and therapeutic means, evolution under treatment and prognostic factors. This study was approved by the Local Ethical Committee. The data were analyzed using Stata/MP 14.1 software.

Results

A total of 198 cases of COVID-19 were identified, 117 of whom were men. The mean age was 51.53 ± 19.51 years. The presenting signs were fever 146 (74.11%), cough 157 (79.70%) and dyspnea 118 (53.90%). It was severe COVID-19 in 108 cases (54.55%). Therapeutically, 95 patients (47.98%) had received the combination of Lopinavir/ritonavir and Ribavirin and 95 others (47.98%) received chloroquine. Recovery was noted in 151 (76.26%) patients. Mortality rate was 18.18%. Predictors of death were high blood pressure, presence of signs of severity, high-concentration mask ventilation used, and elevated transaminases.

Conclusion

COVID-19 was a reality in Parakou, with a significant number of severe cases requiring hospitalization. Several factors are associated with the prognosis of the disease.

World Health Organization: Emergencies diseases. Online. Janv 2021 available at https://www.who.int/emergencies/diseases/novel.

Ciceri F, Castagna A, Rovere-Querini P, De Cobelli F, Ruggeri A, Galli L, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan. Italy Clin Immunol. 2020;217:108509. https://doi.org/10.1016/j.clim.2020.108509.CrossRefPubMed

Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Sushil Rao J, Abrahao-Machado LF, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96:753–8.PubMed

Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F Jr. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021;14(5):601–21. https://doi.org/10.1080/17512433.2021.1902303.CrossRefPubMed

World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report - 11. available at https://www.who.int/docs/defaultsource/corona-virus/situation-reports/. Last accessed october 20, 2021.

Salvadore F, Fiscon G, Paci P. Integro-differential approach for modeling the COVID-19 dynamics - Impact of confinement measures in Italy. Comput Biol Med. 2021;139:105013. https://doi.org/10.1016/j.compbiomed.2021.105013.CrossRefPubMedPubMedCentral

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–42. https://doi.org/10.1001/jama.2020.2648.CrossRefPubMed

Jefferson T, Dooley L, Ferroni E, Al-Ansary LA, van Driel ML, Bawazeer GA et al. Physical interventions to interrupt or reduce the spread of respiratory viruses (Review). Cochrane Database of Systematic Reviews 2023, Issue 1. Art. No.: CD006207.1-10. https://doi.org/10.1136/bmj.b3675.

Scoville C, McCumber A, Amironesei R, Jeon I. Mask Refusal Backlash: The Politicization of Face Masks in the American Public Sphere during the Early Stages of the COVID-19 Pandemic. Socius: Sociological Research for a Dynamic World. 2022;8:1–22. https://doi.org/10.1177/23780231221093.

10.

Binnicker MJ. Challenges and controversies to testing for COVID-19. J Clin Microbiol. 2020;58:e01695-e1720. https://doi.org/10.1128/JCM.01695-20.CrossRefPubMedPubMedCentral

11.

Hamilton MCK, Lyen S, Manghat NE. Controversy in coronaviral imaging and diagnostics (COVID). Clin Radiol. 2020;75(7):557e8.CrossRef

12.

Berlivet L, Löwy I. Hydroxychloroquine controversies: clinical trials, epistemology, and the democratization of science. Med Anthropol Q. 2020;34(4):525–41.CrossRefPubMedPubMedCentral

13.

Castillejos-López M, Torres-Espíndola LM, Huerta-Cruz JC, Flores-Soto E, Romero-Martinez BS, Velázquez-Cruz R, et al. Ivermectin: a controversial focal point during the COVID-19 pandemic. Life. 2022;12:1384. https://doi.org/10.3390/life12091384.CrossRefPubMedPubMedCentral

14.

Benin: WHO Coronavirus Disease (COVID-19) dashboard with vaccination Data. https://covid19.who.int/region/afro/country/bj.

15.

Lodé B, Jalaber C, Orcel T, Morcet-Delattre T, Crespin N, Voisin S, et al. Imagerie de la pneumonie COVID-19. J Imag Diagn Interv. 2020;3(4):249–58.

16.

Kwaghe VG, Habib ZG, Akor AA, Thairu Y, Bawa A, Adebayo FO et al. Clinical characteristics and outcome of the first 200 patients hospitalized with coronavirus disease-2019 at a treatment center in Abuja, Nigeria: a retrospective study. Pan Afr Med J. 2022;41(118). https://doi.org/10.11604/pamj.2022.41.118.26594.

17.

Skripa L, Derrab K, Kaboréc M, Nooria N, Gansanéd A, Valéab I, et al. Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: a retrospective study from Burkina Faso and simulated case analysis. Int J Infect Dis. 2020;101:194–200. https://doi.org/10.1016/j.ijid.2020.09.1432.CrossRef

18.

Hesni E, Sayad B, Khosravi Shadmani F, Najafi F, Khodarahmi R, Rahimi Z, et al. Demographics, clinical characteristics, and outcomes of 27,256 hospitalized COVID-19 patients in Kermanshah Province, Iran: a retrospective one-year cohort study. BMC Infect Dis. 2022;22(1):319. https://doi.org/10.1186/s12879-022-07312-7.CrossRefPubMedPubMedCentral

19.

Halatoko WA, Konu YR, Gbeasor-Komlanvi FA, Sadio AJ, Tchankoni MK, Komlanvi KS, et al. Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020. PLoS One. 2020;15(11):e0242124. https://doi.org/10.1371/journal.pone.0242124.CrossRefPubMedPubMedCentral

20.

MveangNzoghe A, Padzys G-S, MaloupazoaSiawaya AC, Yattara MK, Leboueny M, Houechenou RMA, et al. Dynamic and features of SARS-CoV-2 infection in Gabon. Nat Sci Rep. 2021;11:9672. https://doi.org/10.1038/s41598-021-87043-y.CrossRef

21.

Erinoso OA, Wright KO, Anya S, Bowale A, Adejumo O, Adesola S, et al. Clinical characteristics, predictors of symptomatic coronavirus disease 2019 and duration of hospitalisation in a cohort of 632 Patients in Lagos State. Nigeria Nig Postgrad Med J. 2020;27(4):285–92. https://doi.org/10.4103/npmj.npmj_272_20.CrossRef

22.

Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34(2):339–43. https://doi.org/10.23812/editorial-conti-3.CrossRefPubMed

23.

Jaspard M, Sow MS, Juchet S, Dienderé E, Serra B, Kojan R, COVISTA study group, et al. Clinical presentation, outcomes and factors associated with mortality: a prospective study from three COV4ID-19 referral care centres in West Africa. Int J Infect Dis. 2021;108:45–52. https://doi.org/10.1016/j.ijid.2021.05.024.CrossRefPubMedPubMedCentral

24.

Otuonye NM, Olumade TJ, Ojetunde MM, Holdbrooke SA, Joy BoluwatifeAyoola JB, et al. Clinical and Demographic Characteristics of COVID-19 patients in Lagos, Nigeria: a Descriptive Study. J National Med Assoc. 2021;113(3):301–6. https://doi.org/10.1016/j.jnma.2020.11.011.CrossRef

25.

Khamis F, Memish Z, Al Bahrani M, Al Dowaiki S, Pandaka N, Al Bolushi Z, et al. Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection. J Infect Public Health. 2021;14:759–65. https://doi.org/10.1016/j.jiph.2021.03.016.CrossRefPubMedPubMedCentral

26.

Marin BG, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID-19 severity: a literature review. Rev Med Virol. 2020;31(1):e2146. https://doi.org/10.1002/rmv.2146.CrossRef

27.

Mbarga FN, Epee E, Mbarga M, Ouamba P, Nanda H, Nkengni A, et al. Clinical profile and factors associated with COVID-19 in Yaounde, Cameroon: a prospective cohort study. PLoS One. 2021;16(5):e0251504. https://doi.org/10.1371/journal.pone.0251504.CrossRefPubMedPubMedCentral

28.

Haïdara DBS, Traore M, Cissouma A, Mariko ML, Kante M, Touré L, et al. Covid-19: Aspects épidémio-cliniques, thérapeutiques et évolutifs des patients pris en charge. Cas de l’Hôpital de Sikasso – Mali. Rev Mali Infect Microbiol. 2022;17(1):17–23. https://doi.org/10.53597/remim.v17i1.2217.CrossRef

29.

Samaké D, Coulibaly M, Kéita M, Guindo O, Dembélé M, Traoré A, et al. COVID-19 à Mopti: aspects épidémiologique, clinique, thérapeutique et évolutif. Rev Mali Infect Microbiol. 2021;16:47–51. https://doi.org/10.53597/remim.v16i1.1760.CrossRef

30.

Arshada S, Kilgoreb P, Zohra S, Chaudhrya ZS, Jacobsene G, Wangd DD, Huitsinga K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396–403. https://doi.org/10.1016/j.ijid.2020.06.099.CrossRef

31.

Yu B, Li C, Chen P, Zhou N, Wang L, Li J, et al. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. Medrxiv preprint. 2020. https://doi.org/10.1101/2020.04.27.20073379.CrossRef

32.

Axfors C, Schmitt AM, Janiaud P, van’tHooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international, collaborative meta-analysis of randomized trials. Nature Communications. 2021;12:2349. https://doi.org/10.1038/s41467-021-22446-z.CrossRefPubMedPubMedCentral

33.

Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030–40. https://doi.org/10.1056/nejmoa2022926.CrossRefPubMed

34.

Shah R, Shah J, Kunyiha N, Ali SK, Sayed S, Surani S, et al. Demographic, clinical, and co-morbidity characteristics of COVID-19 patients: a retrospective cohort from a tertiary hospital in Kenya. Int J Gen Med. 2022;15:4237–46. https://doi.org/10.2147/ijgm.s361176.CrossRefPubMedPubMedCentral

35.

Umakanthan S, Senthil S, John S, Madhavan MK, Das J, Patil S, et al. The effect of statins on clinical outcome among hospitalized patients with COVID-19: a multi-centric cohort study. Front Pharmacol. 2022;13:742273. https://doi.org/10.3389/fphar.2022.742273.CrossRefPubMedPubMedCentral

36.

Leulseged TW, Hassen IS, Maru EH, Zewsde WC, Chamiso NW, Bayisa AB, et al. (2021) Characteristics and outcome profile of hospitalized African patients with COVID-19: the Ethiopian context. PLoS ONE. 2021;16(11):e0259454. https://doi.org/10.1371/journal.pone.0259454.CrossRefPubMedPubMedCentral

37.

Fua L, Wanga B, Yuana T, Chenf X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020;80:656–65. https://doi.org/10.1016/j.jinf.2020.03.041.CrossRef

38.

Thai PQ, Toan DTT, Son DT, Van HTH, Minh LN, Hung LX, et al. Factors associated with the duration of hospitalisation among COVID-19 patients in Vietnam: a survival analysis. Epidemiol Infect. 2020;148(e114):1–7. https://doi.org/10.1017/s0950268820001259.CrossRef

39.

Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy. Italy JAMA Intern Med. 2020;180(10):1345–55. https://doi.org/10.1001/jamainternmed.2020.3539.CrossRefPubMed

Title: Epidemiological, clinical, therapeutic features and predictors of death among COVID-19 patients hospitalized in Parakou: a cross-sectional study in Northern Benin
Authors: Attinsounon Cossi Angelo
Yamongbè Clodel
Codjo Léopold
Adé Serge
Mama Cissé Ibrahim
Attinon Julien
Klikpezo Roger
Savi de Tovè Kofi-Mensa
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: COVID-19
Chloroquin
Chloroquin
Ribavirin
Ritonavir
Published in: BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-023-08445-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Pathogens in PICU before and during the SARS-CoV-2 pandemic in China: a multicenter retrospective study

Kidney invasion occurred 2 years following liver transplantation for hepatic alveolar echinococcosis: a case report

Disseminated nocardiosis in a patient with alcoholic liver cirrhosis: a case report

Influence of herd immunity on norovirus: a long-term field study of repeated viral gastroenteritis outbreaks at the same facilities

Characteristics and outcomes in adult patients with Staphylococcus lugdunensis bacteremia compared to patients with Staphylococcus epidermidis and Staphylococcus aureus bacteremia: a retrospective study in a 16-year period at the university hospital, Japan

Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials